anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The proper method of administration of ZOLADEX is described in the instructions that follow. 

  1. Put the patient in a comfortable position with the upper part of the body slightly raised. Prepare an area of the anterior abdominal wall below the navel line with an alcohol swab.  
NOTE: Caution should be taken while injecting ZOLADEX into the anterior abdominal wall due to the proximity of underlying inferior epigastric artery and its branches. 
  2. Examine the foil pouch and syringe for damage. Remove the syringe from the opened foil pouch and hold the syringe at a slight angle to the light. Check that at least part of the ZOLADEX implant is visible. 
  3. Grasp the red plastic safety tab and pull away from the syringe, and discard. Remove needle cover. Unlike liquid injections, there is no need to remove air bubbles as attempts to do so may displace the ZOLADEX implant. 
  4. Holding the syringe around the protective sleeve, using an aseptic technique, pinch the skin of the patient's anterior abdominal wall below the navel line. With the bevel of the needle facing up, insert the needle at a 30 to 45 degree angle to the skin in one continuous deliberate motion until the protective sleeve touches the patient's skin.  
NOTE: The ZOLADEX syringe cannot be used for aspiration. If the hypodermic needle penetrates a large vessel, blood will be seen instantly in the syringe chamber. If a vessel is penetrated, withdraw the needle and inject with a new syringe elsewhere. Monitor patients for signs or symptoms of abdominal hemorrhage. Use extra care when administering ZOLADEX to patients with a low BMI and/or to patients receiving full dose anticoagulation [see Warnings and Precautions (5.9)].
  5. Do not penetrate into muscle or peritoneum. 
  6. To administer the ZOLADEX implant and to activate the protective sleeve, grasp the barrel at the finger grip and depress the plunger until you cannot depress it any further. If the plunger is not depressed fully, the protective sleeve will NOT activate. When the protective sleeve ‘clicks’, the protective sleeve will automatically begin to slide to cover the needle.  
NOTE: The needle does not retract. 
  7. Withdraw the needle and allow protective sleeve to slide and cover needle. Dispose of the syringe in an approved sharps collector. 



NOTE: In the unlikely event of the need to surgically remove ZOLADEX, it may be localized by ultrasound.
A method for extracting oil from sea cucumber material is provided. The sea cucumber material is mixed with water and the mixture is heated at a predetermined heating temperature for a predetermined heating time interval. The pH value and temperature of the mixture are adjusted to be compatible with an enzyme. A predetermined amount of the enzyme is then added to the mixture. The mixture is incubated at a predetermined incubation temperature for a predetermined incubation time interval. After the incubation the oil is removed from the mixture.
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to therapy and physiotherapy, and can be used to treat patients with metabolic syndrome. Preliminary tests are carried out by the vegetative resonance test method after finding the reproducible measurement point using the organ preparation “Adipose tissue”. In this case, all parameters of the metabolism are tested consecutively and in inversion, selecting the parameters characteristic for the optimal reduction of the fat tissue volume in this patient. They select an individual food complex that reduces the volume of adipose tissue, including in the first month in the diet products with a glycemic index of less than 40, in the second and subsequent months – products with a higher glycemic index. Next, a general air cryotherapy (OCT) is carried out in combination with individually selected nutrition and drug therapy. In this case, OCT is carried out at a temperature of -120 °C to -190 °C by subtotal immersion of the patient in an open loop cryocamera with an exposure of 1 to 3 minutes. In addition, in 5–10 minutes after the patient leaves the cryocamera, local cryotherapy of the skin is performed in the area of the cervical-collar zone, the anterior abdominal wall and cellulite-altered skin. In this case, the effect is carried out by a dry air jet at a temperature of -170 °C at the outlet of the device nozzle or contact equipment before the appearance of a white ischemic spot, carrying out a smooth management of the ischemic spot on the surface of the skin. Course of treatment includes 14 to 30 procedures.EFFECT: method ensures increase in effectiveness of treatment due to the pronounced effect on the main links of the regulation of the trigger mechanism of the metabolic syndrome, and, as a consequence, on its main symptoms and manifestations, namely abdominal-visceral obesity, insulin resistance and hyperinsulinemia, dyslipidemia, arterial hypertension, impaired glucose tolerance, early atherosclerosis, IHD, hemostasis disorder, hyperuricemia and gout, microalbuminuria, hyperandrogenism.1 cl, 6 ex, 1 tbl
PURPOSE:A growth promotor for domestic fowls effective, for promoting growth of domestic fowls, for preventing and remedying salmonellosis of domestic fowls, containing a culture mold of a specific bacterium of the genus Clostridium as an active ingredient. CONSTITUTION:A growth promotor for domestic fowls containing a culture mold of Clostridium innocuum or Clostridium symbiosum, or their mixture as an active ingredient. The two bacteria are obligates, and its cultivation is carried out under unaerobic conditions. For example, a mixed solution of L-cysteine hydrochloride and ascorbic acid is added to a medium immediately after heat sterilization, dissolved oxygen in the medium is removed, and the bacterium is cultivated under unaerobic conditions. The cultivation is carried out at 30-42 deg.C at pH close to neutrality. After the cultivation is over, the culture solution is cooled, the mold is separated and recovered by centrifugation. It is not only effective for promoting growth but also for preventing and remedying salmonellosis of domestic fowls.
Closely monitored clinical experience with fluvoxamine maleate tablets in patients with concomitant systemic illness is limited. Caution is advised in administering fluvoxamine maleate tablets to patients with diseases or conditions that could affect hemodynamic responses or metabolism. 

Fluvoxamine maleate tablets have not been evaluated or used to any appreciable extent in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were systematically excluded from many clinical studies during the product's premarketing testing. Evaluation of the electrocardiograms for patients with depression or OCD who participated in premarketing studies revealed no differences between fluvoxamine and placebo in the emergence of clinically important ECG changes. 

Patients with Hepatic Impairment - In patients with liver dysfunction, fluvoxamine clearance was decreased by approximately 30%. Patients with liver dysfunction should begin with a low dose of fluvoxamine maleate tablets and increase it slowly with careful monitoring.
The experimental group will immediately start using the GGSI app, for a period of 15 days (T1). After 15 days (T2) the experimental group ceases its use of the app. The end of this period is marked T3. The research team will contact the experimental group on T1, T2 and T3 in order to fill out questionnaires regarding suicide ideation and related risk factors.
Obesity is the primary risk factor for the development of obstructive sleep apnea, and physical inactivity plays an important role. However, most studies have either only evaluated physical activity subjectively or objectively in obstructive sleep apnea. The objectives of this study were: (i) to assess the relationship between obstructive sleep apnea severity (both apnea-hypopnea index and desaturation parameters) and both objectively and subjectively measured physical activity after adjustment for anthropometry and body composition parameters; and (ii) to assess the relationship between objective and subjective physical activity parameters and whether obstructive sleep apnea severity has a modulatory effect on this relationship. Fifty-four subjects (age 47.7 ± 15.0 years, 46% males) were categorized into groups according to obstructive sleep apnea severity: no obstructive sleep apnea; mild obstructive sleep apnea; and moderate-to-severe obstructive sleep apnea. All subjects were evaluated with subjective and objective physical activity, anthropometric and body composition measurements, and 3-night self-applied polysomnography. A one-way ANOVA was used to evaluate the differences between the three obstructive sleep apnea severity groups and multiple linear regression to predict obstructive sleep apnea severity. Differences in subjectively reported sitting time (p ≤ 0.004) were found between participants with moderate-to-severe obstructive sleep apnea, and those with either mild or no obstructive sleep apnea (p = 0.004). Age, body mass index and neck circumference explained 63.3% of the variance in the apnea-hypopnea index, and age, body mass index and visceral adiposity explained 67.8% of the variance in desaturation parameters. The results showed that the person's physical activity does not affect obstructive sleep apnea severity. A weak correlation was found between objective and subjective physical activity measures, which could be relevant for healthcare staff encouraging patients with obstructive sleep apnea to increase their physical activity.
Three double-blind, active- and placebo-controlled studies were conducted in 416 children aged 6 to 12 years. The controlled studies compared methylphenidate hydrochloride extended-release tablets given once daily (18, 36, or 54 mg), methylphenidate given three times daily over 12 hours (15, 30, or 45 mg total daily dose), and placebo in two single-center, 3-week crossover studies (Studies 1 and 2) and in a multicenter, 4-week, parallel-group comparison (Study 3). The primary comparison of interest in all three trials was methylphenidate hydrochloride extended-release tablets versus placebo. 

Symptoms of ADHD were evaluated by community schoolteachers using the Inattention/Overactivity with Aggression (IOWA) Conners scale. Statistically significant reduction in the Inattention/Overactivity subscale versus placebo was shown consistently across all three controlled studies for methylphenidate hydrochloride extended-release tablets. The scores for methylphenidate hydrochloride extended-release tablets and placebo for the three studies are presented in Figure 2.

Figure 2. Mean Community School Teacher IOWA Conners Inattention/Overactivity Scores with methylphenidate hydrochloride extended-release tablets once-daily (18, 36, or 54 mg) and placebo. Studies 1 and 2 involved a 3-way crossover of 1 week per treatment arm. Study 3 involved 4 weeks of parallel-group treatments with a Last Observation Carried Forward analysis at week 4. Error bars represent the mean plus standard error of the mean. 

In Studies 1 and 2, symptoms of ADHD were evaluated by laboratory schoolteachers using the SKAMP* laboratory school rating scale. The combined results from these two studies demonstrated statistically significant improvements in attention and behavior in patients treated with methylphenidate hydrochloride extended-release tablets versus placebo that were maintained through 12 hours after dosing. Figure 3 presents the laboratory schoolteacher SKAMP ratings for methylphenidate hydrochloride extended-release tablets and placebo. 

*Swanson, Kotkin, Agler, M-Fynn and Pelham

Figure 3. Laboratory School Teacher SKAMP Ratings: Mean (SEM) of Combined Attention (Studies 1 and 2)
Laparoscopic Myotomy + Dor anterior partial fundoplication. 90 degree partial fundoplication being the standard of care.
Eligible patients will start treatment with lenvatinib 18 mg PO daily (administered as one 10 mg capsule and two 4 mg capsules) and everolimus 5 mg PO daily for 4 weeks constituting one cycle. Two cycles of treatment will be administered and after 2 weeks wash out period, the patients will go for nephrectomy.
Subjects will be provided an Oculus Go VR headset pre-loaded two-dimensional nature video. Subjects are required to use the VR headset at home four times daily, prior to breakfast, lunch, dinner, and bedtime. Each session will last approximately 15 minutes.
A depilatory for use in removing hair from the body comprises a non-depilating vehicle carrying thioglycerol (HS.CH2. CH(OH).CH2OH or (HOCH2)2HCSH)-and sufficient alkyline reacting-material to impart a pH value between 9 and 12.5 to the preparation.  The thioglycerol is used in amount not less than 0.1 mole per litre and the desired bases, preferably having an ionization constant exceeding 2.0 x 10- 5 including hydroxides of the alkali and alkaline earth metals, are used in amount not greater than twice the acidic equivalent of the thioglycerol.  The stronger bases such as strontium or sodium hydroxide may be used to wholly or partly neutralise the acidity of the thioglycerol while lime paste or calcium hydroxide may supply the excess alkalinity and alkalinity reservoir, of which a part (20-50 per cent.) may preferably be replaced by fillers e.g. precipitated chalk, magnesium oxide, clays, talcs and pyrophillites.  Natural gums and preferably water dispersible polyvinyl alcohols and cellulose ethers (1-10 per cent.) may be incorporated in the pastes and in the emulsions formed by dispersing a fatty alkyl alcohol with an emulsifier e.g. fatty alkyl sulphate.  Perfumes may also be added. The composition comprises in example (1) strontium hydrate, calcium oxide, colloidal clay, methyl cellulose, thio-glycerol, water and perfume, and in example (2) fatty alcohol, sodium fatty alkyl sulphate alkaline earth hydroxide, morganic fillers, thio-glycerol, perfume and water to form suitable consistency Specification 521,240 is referred to.  The Specification as open to inspection under Sect. 91 describes also the removal of hair by treating first with thioglycerol solution and later with an alkaline medium, e.g., lime putty. This subject-matter does not appear in the Specification as accepted.
The invention relates to a traditional Chinese medicine, that is a soft capsule of Chinese thorowax and baicalin extractive, and a method of quality control thereof. The traditional Chinese medicine consists of the following ingredients according to the weight content: 1,250 grams of Chinese thorowax, 90 grams of baicalin extractive (in terms of baicalin), 40 grams of propanediol and 300 to 500 grams of carmowax 400. The method of quality control consists of qualitative authentication and content measurement. The soft capsule of Chinese thorowax and baicalin extractive has the characteristics that the taking is convenient, the bioavailability is high and no restriction is exerted to the capsule user. A diluting agent is preferably selected to make the capsule neither too hard nor too soft and make the quality stable. Simultaneously, the Chinese thorowax in the formula is conducted an aqueous extraction and ethanol sediment and baicalin is charged as an extractive, which is fit to be made into a soft capsule with a novel preparation formulation and improved curative effect. The method of quality control can control the active ingredients of the soft capsule of Chinese thorowax and baicalin extractive effectively; moreover, the method is stable and reliable and has strong specificity, thereby enhancing the overall quality of the soft capsule of Chinese thorowax and baicalin extractive greatly and guaranteeing the curative effect.
In wildlife populations, parasites often go unnoticed, as infected animals appear asymptomatic. However, these infections can subtly alter behaviour. Field evidence of how these subclinical infections induce changes in movement behaviour is scarce in free-ranging animals, yet it may be crucial for zoonotic disease surveillance. We used an ultra-high-resolution tracking system (ATLAS) to monitor the movements of 60 free-ranging swallows every 8 seconds across four breeding seasons, resulting in over 1 million localizations. About 40% of these swallows were naturally infected with haemosporidian parasites. Here, we show that infected individuals had reduced foraging ranges, foraged in lower quality habitats, and faced a lowered survival probability, with an average reduction of 7.4%, albeit with some variation between species and years. This study highlights the impact of subclinical infections on movement behaviour and survival, emphasizing the importance of considering infection status in movement ecology. Our findings provide insights into individual variations in behaviour and previously unobservable local parasite transmission dynamics.
Exercising women have a high prevalence of menstrual disturbances. In 2003, it was suggested that disruption in luteinizing hormone (LH) pulsatility occurs below a threshold of energy availability (EA) of 30 kcal/kg lean body mass (LBM)/day. This paper is a critical review of the evidence regarding the theory that disruptions to the reproductive axis and menstrual disturbances occur below the proposed threshold. Short-term laboratory studies demonstrated that 4-5 days of an EA below 30 kcal/kg LBM/day, induced with or without exercise, decreased serum triiodothyronine and LH pulse frequency, and increased LH pulse amplitude in sedentary, regularly menstruating women. Fewer studies have investigated downstream ovarian effects after long-term exposure to low EA. The Sargent Camp Study was the first randomized trial that induced luteal phase defects, delayed menses, and anovulation by causing weight loss (-4 ± 0.3 kg) with an abrupt increase in exercise volume for two menstrual cycles. The BioEnergetics Study was a randomized controlled trial that induced varying levels of energy deficits by manipulating energy intake and expenditure for three menstrual cycles. LH pulse frequency and triiodothyronine decreased, and 57% of women developed luteal phase defects, anovulation, and/or oligomenorrhea. An EA below 30 kcal/kg fat free mass/day increased the chance of experiencing a menstrual disturbance by 50%. However, menstrual disturbances were observed above and below that EA threshold, and changes in LH pulse frequency predicted only luteal phase defects, not oligomenorrhea or anovulation. The proposed EA threshold is not a cut-off below which menstrual disturbances occur, but represents an increased risk of experiencing menstrual disturbances.
Functional Family Therapy (FFT) is a brief treatment for youth with problem behaviors, including substance abuse that consists of 12 to 14 weekly family sessions. The FFT treatment is applied in five distinct phases: Engagement, Motivation, Relational Assessment, Behavior Change, and Generalization and each phase has specific goals, techniques, and therapist skills.
BACKGROUND: Septic shock is associated with high morbidity and mortality, the endothelium plays an important role. Crystalloids is standard of care to maintain intravascular volume. Plasma is associated with improved endothelial integrity and restoration of the glycocalyx layer. We evaluated the efficacy and safety aspects of cell-free and pathogen inactivated pooled plasma (OctaplasLG®) as resuscitation in septic shock patients.
STUDY DESIGN AND METHODS: This randomized, investigator-initiated phase IIa trial ran at a Danish single center intensive care unit, from 2017 to 2019. Patients were 18 years of age or older with septic shock and randomized to fluid optimization with OctaplasLG® or Ringer-acetate in the first 24 h. The primary endpoints were changes in biomarkers indicative of endothelial activation, damage, and microvascular perfusion from baseline to 24 h. Safety events and mortality were assessed during 90 days.
RESULTS: Forty-four patients were randomized, 20 to OctaplasLG versus 24 to Ringer-acetate. The median age was 69, and 55% were men. Median Sequential Organ Failure Assessment score was 13. Baseline differences favoring the Ringer-acetate group were observed. The OctaplasLG® group was resuscitated with 740 mL plasma and the Ringer-acetate group with 841 mL crystalloids. There was no significant change in the microvascular perfusion or five biomarkers except VEGFR1 change, which was higher in patients receiving OctaplasLG® 0.12(SD 0.37) versus Ringer-acetate -0.24 (SD 0.39), with mean difference 0.36 (95% CI, 0.13-0.59, p = .003) in favor of Ringer-acetate.
DISCUSSION: This study found that fluid resuscitation with OctaplasLG® in critically ill septic shock patients is feasible. Baseline confounding prevented assessment of the potential effect of OctaplasLG®.
Immune cells are an important part of the abnormal autoimmune response in SLE. The B cell is a significant part of this autimmune response because it produces the antibodies which can react with normal tissue of the body. B cells have the ability to accumulate and promote the development of SLE. The purpose of this study is to determine how B cell subsets and autoantibodies are related to disease remission after rituximab treatment in subjects with SLE.

This study will last approximately two years and consist of 15 study visits. These visits will occur at screening, baseline, Days 0 and 14, and Months 1, 2, 3, 4, 6, 9, 12, 15, 18, 21, and 24. Participants will receive a single rituximab injection on Days 0 and 14. Medication history and blood tests will occur at every study visit. A physical exam, medical history, and urine tests will occur at most visits. For females, a pregnancy test will occur at selected visits.
PURPOSE: Current studies of the efficacy of scalp cooling are limited by short-term duration. Therefore, we conducted a randomized controlled trial to evaluate the efficacy of scalp cooling in reducing persistent chemotherapy-induced alopecia (PCIA) 6 months after chemotherapy.
METHODS: We conducted an open-label randomized controlled trial comparing scalp cooling versus control in newly diagnosed patients with breast cancer stages I-III scheduled to receive neoadjuvant or adjuvant chemotherapy with curative intent between December 2020 and August 2021. Patients were randomly assigned (2:1 ratio) to scalp cooling or usual clinical practice. The primary outcome was PCIA 6 months after chemotherapy. Hair thickness and density were measured using Folliscope 5.0. CIA-related distress was assessed using the CIA distress scale (CADS), with a higher score reflecting higher stress.
RESULTS: The proportion of patients with PCIA at 6 months was 13.5% (12/89) in the scalp-cooling group and 52.0% (26/50) in the control group. The average difference in the change in hair thickness from baseline between the scalp-cooling and control groups was 9.0 μm in favor of the intervention group. The average difference in the change in hair density between intervention and control at the end of the study was -3.3 hairs/cm2. At 6 months after chemotherapy, the average difference in the change in CADS score between the intervention and control groups was -3.2 points, reflecting reduced CIA-related stress in the intervention group.
CONCLUSION: Scalp cooling reduced the incidence of PCIA, primarily by increasing hair thickness compared with control. Scalp cooling is helpful in promoting qualitative hair regrowth. Yet, further research is necessary to observe longer-term benefits of scalp cooling.